<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00459849</url>
  </required_header>
  <id_info>
    <org_study_id>HRPO# 07-0092</org_study_id>
    <nct_id>NCT00459849</nct_id>
  </id_info>
  <brief_title>Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma</brief_title>
  <official_title>Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barnes Retina Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barnes Retina Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Plaque radiotherapy is a common treatment for uveal melanoma. However, local failure has been
      reported in up to 20% of patients. We use intraoperative ultrasonography at plaque insertion
      and removal to evaluate plaque movement as a potential factor in local failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Episcleral plaque radiotherapy is a common treatment for uveal melanoma and results in local
      tumor control in most cases. However, local failure has been reported in a substantial
      proportion of patients. Since local failure greatly increases the risk of metastatic death,
      identifying and correcting the causes of local treatment failure are of paramount importance.
      Poor plaque localization is an important contributing factor to local failure. With the aid
      of intraoperative ultrasonography, most malpositioned plaques can be identified and
      readjusted at the time of plaque insertion. However, little is known about plaque movement
      during the 4-5 days of brachytherapy, which could also contribute to local failure. To
      address this question, we perform intraoperative B-scan ultrasonography at the time of
      iodine-125 radioactive plaque insertion and removal in uveal melanoma patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2000</start_date>
  <completion_date type="Anticipated">July 2007</completion_date>
  <primary_completion_date type="Anticipated">July 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plaque tilt using intraoperative ultrasonography</measure>
    <time_frame>End of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local melanoma failure</measure>
    <time_frame>End of study</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Uveal Melanoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intraoperative ultrasonography</intervention_name>
    <description>Intraoperative ultrasonography will be used to determine plaque placement.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with uveal melanoma treated with brachytherapy

        Exclusion Criteria:

          -  Ciliary melanoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J W Harbour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University in St. Louis School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Harbour JW. Clinical overview of uveal melanoma: introduction to tumors of the eye. In: Albert DM, Polans A, eds. Ocular Oncology. New York: Marcel Dekker; 2003:1-18.</citation>
  </reference>
  <reference>
    <citation>Char DH, Quivey JM, Castro JR, Kroll S, Phillips T. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology. 1993 Oct;100(10):1547-54.</citation>
    <PMID>8414414</PMID>
  </reference>
  <reference>
    <citation>Garretson BR, Robertson DM, Earle JD. Choroidal melanoma treatment with iodine 125 brachytherapy. Arch Ophthalmol. 1987 Oct;105(10):1394-7.</citation>
    <PMID>3310986</PMID>
  </reference>
  <reference>
    <citation>Karlsson UL, Augsburger JJ, Shields JA, Markoe AM, Brady LW, Woodleigh R. Recurrence of posterior uveal melanoma after 60Co episcleral plaque therapy. Ophthalmology. 1989 Mar;96(3):382-8.</citation>
    <PMID>2710530</PMID>
  </reference>
  <reference>
    <citation>Quivey JM, Augsburger J, Snelling L, Brady LW. 125I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control. Cancer. 1996 Jun 1;77(11):2356-62.</citation>
    <PMID>8635107</PMID>
  </reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2007</study_first_submitted>
  <study_first_submitted_qc>April 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2007</study_first_posted>
  <last_update_submitted>May 6, 2008</last_update_submitted>
  <last_update_submitted_qc>May 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Archavan Almony, M.D.</name_title>
    <organization>Barnes Retina Institute</organization>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Brachytherapy</keyword>
  <keyword>Ultrasonography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

